Methods for inhibiting conversion of choline to trimethylamine (tma)

A method of inhibiting the conversion of choline to trimethylamine and reducing trimethylamine N-oxide level in an individual comprising administering to the individual a composition comprising a compound set forth in Formula (I):

• wherein:
• n=0, 1,2 or 3;
• for n=0, R1 and R2 are independently selected from C1-C4 alkyl and R3 is selected from allyl, propargyl or alkyl nitrile;
• for n=1, 2, or 3, R1 and R2 are independently selected from C1-C4 alkyl, C1-C4 heteroalkyl, allyl, heteroallyl, aryl, alkenyl, heteroalkenyl, alkynyl, halo, alkoxy, carboxyl, carboxylate, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, hydroxyl, propargyl and when bound together, can form part of an aliphatic or heterocyclic ring system;
• R3 is selected from allyl, alkenyl, alkynyl, amino alkyl, aryl, aryl alkyl, alkoxy alkyl, carboxy alkyl, C4-C6 alkyl, hydroxy alkyl or C1-C3 alkyl when [S+] is part of a heterocyclic ring, halo alkyl, halo alkenyl, propargyl, substituted aryl, or bonded oxygen [O] when S is a sulfoxide;
• X− is a pharmaceutically acceptable anion, when the compound of interest exists as a sulfoxide, then X− is absent,
• and including any salts or solvates thereof,
• wherein the compound is administered in an amount effective to inhibit formation of trimethylamine from choline in the individual.

A method of improving a condition associated with the conversion of choline to trimethylamine in an individual comprising administering to the individual a compound set forth in Formula (I):

• wherein:
• n=0, 1,2 or 3;
• for n=0, R1 and R2 are independently selected from C1-C4 alkyl and R3 is selected from allyl, propargyl or alkyl nitrile;
• for n=1, 2, or 3, R1 and R2 are independently selected from C1-C4 alkyl, C1-C4 heteroalkyl, allyl, heteroallyl, aryl, alkenyl, heteroalkenyl, alkynyl, halo, alkoxy, carboxyl, carboxylate, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, hydroxyl, propargyl and when bound together, can form part of an aliphatic or heterocyclic ring system;
• R3 is selected from allyl, alkenyl, alkynyl, amino alkyl, aryl, aryl alkyl, alkoxy alkyl, carboxy alkyl, C4-C6 alkyl, hydroxy alkyl or C1-C3 alkyl when [S+] is part of a heterocyclic ring, halo alkyl, halo alkenyl, propargyl, substituted aryl, or bonded oxygen [O] when S is a sulfoxide;
• X− is a pharmaceutically acceptable anion, when the compound of interest exists as a sulfoxide, then X− is absent,
• and including any salts or solvates thereof,
• wherein the compound is administered in an amount effective to treat or prevent the disease or condition associated with choline-related trimethylamine in the individual.